Theorem Clinical Research has announced the formation of a strategic alliance with Decision Driver Analytics (DDA) to integrate health economics and outcomes research, predictive modeling and definitive analysis to maximize return on investment for pharmaceutical and medical device research programs.
Decision Driver Analytics was founded in 2006 by Elizabeth Brooks, Ph.D., to provide accessible health economics analysis and strategies to drive product decisions for manufacturers and developers.
Lee Spurgin, SVP and General Manager of Theorem’s Medical Device and Diagnostic Development, told Outsourcing-Pharma.com, “I’m pulling together a group of individuals to be a one-stop for device companies with clinical trials.”
He added that Ms. Brooks “allows us to look at protocol, design methodologies and determine how to save clients money. The device community has been hit over the past 24 months in terms of failures, especially for our key clients.”
Ms. Brooks and her team are “focused on reimbursement trends and economic outcomes on certain products,” Spurgin added. “We met with a large client in the Bay Area two weeks ago and they want to reduce oversight time.”
“It’s a mechanism of the design of the trial and the design of the device. As we’ve evolved, we’re seeing where [a device] works in a portion of the population but not for the long-term,” he said. “The data show some of these devices might not be as effective as once thought. But Decision Driver has seen very different models, questioning the endpoints” of some trials.
King of Prussia-based Theorem’s move comes nearly a month since forming its strategic alliance with BioTelemetry, which includes the global cardiac core laboratory known as Cardiocore.
“Knowing the right answers to key questions at critical decision points in the development process can make the difference between having the latest blockbuster or an expensive failure,” John Potthoff, president and CEO of Theorem Clinical Research , said. “We believe this alliance helps drive projects for clients in ways that will achieve both regulatory and marketing success.”